Gastric cancer vaccine trial in Singapore
SINGAPORE: A new gastric cancer vaccine being developed could provide gastric cancer patients with an alternative treatment option. Currently, treatment for advanced gastric cancer is limited to surgery and chemotherapy - often with side effects such as fatigue and hair loss. The vaccine is now in the early phase of clinical trial, and the first patient to undergo the trial was recruited in early June. More 30 more patients will be picked over the next two years for the trial. The vaccine study is conducted by clinicians from the Haemotology-Oncology Research Group (HORG) at the National University Cancer Institute, and Japanese biomedical company, OncoTherapy Science Inc (OTS) Every year, more than 600 people in Singapore are diagnosed with gastric cancer, with about 400 succumbing to the disease.